Lilly Tirzepatide: Portfolio, Indications, and Context

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub, our resource for evidence-based coverage of GLP-1 therapies, weight-management protocols, and the genetics behind metabolic decisions. Browse all Peptides & GLP-1 education for more.

Tirzepatide is Eli Lilly's flagship molecule in the GLP-1 receptor agonist space, and as of April 2026 Lilly is one of the two largest manufacturers in that landscape. This article maps Lilly's tirzepatide brands, their FDA-approved indications, how they stack up against Novo Nordisk, and the genetic variables that sit upstream of any GLP-1 pathway compound regardless of who makes it.

Where tirzepatide fits in Lilly's portfolio

Eli Lilly markets tirzepatide under two brands. Mounjaro is FDA-approved for type 2 diabetes, cleared in 2022. Zepbound is FDA-approved for chronic weight management, cleared in 2023, and for obstructive sleep apnea in adults with obesity, added in December 2024. Lilly also markets Trulicity (dulaglutide), a GLP-1-selective option approved for type 2 diabetes in 2014 with a cardiovascular indication added in 2020.

The investigational pipeline

Lilly's pipeline includes orforglipron, an oral non-peptide GLP-1 receptor agonist in Phase 3, and retatrutide, a GLP-1/GIP/glucagon triple agonist also in Phase 3. Retatrutide is investigational and not FDA-approved, and PlexusDx does not sell it.

What makes tirzepatide molecularly distinct

Tirzepatide is the only FDA-approved GIP/GLP-1 dual agonist, which sets Lilly's strategy apart from Novo Nordisk's focus on GLP-1-selective compounds such as semaglutide and liraglutide. Lilly covers both bases, offering the dual agonist in tirzepatide and a GLP-1-selective option in dulaglutide. Head-to-head trials — SURPASS-2, comparing tirzepatide with semaglutide 1 mg in type 2 diabetes, and SUSTAIN 7, comparing semaglutide with dulaglutide — inform the competitive picture, though direct weight-management head-to-head data remains limited.

Cost and safety at the class level

Manufacturer list prices are broadly similar across branded products, typically $800-$1,600 per month at U.S. list as of April 2026. Savings card programs differ by product, and patient assistance programs exist for eligible uninsured or underinsured patients. Compounded alternatives through 503A pharmacies are priced separately.

The shared boxed warning

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, and rare serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

The genetic context upstream of any brand

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, including the Tirzepatide Injection. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. These pathway-level associations never predict response to any manufacturer's product, and the test applies through 503A compounding only.

Keep reading on PlexusDx: Mounjaro GLP-1, Mounjaro Pill, and Good Rx Mounjaro.

What the landscape means for patients

For a patient, the manufacturer's name usually matters less than the indication and coverage attached to a specific product. Knowing that Mounjaro and Zepbound both contain tirzepatide, while carrying different approved uses, helps explain why one might be covered and another might not, even though the molecule is identical across both.

The competitive picture between Lilly and Novo Nordisk is useful mostly as background. Trials such as SURPASS-2 and SUSTAIN 7 compare particular products in particular populations, and averages from those studies do not translate directly to any one person's result. A clinician who can weigh your personal factors is better positioned than a head-to-head headline to guide the decision.

If there is one practical habit worth adopting, it is to anchor on the specific product and its indication rather than on brand loyalty or manufacturer reputation. The molecule, the approved use, and your own coverage are what shape the real decision, and a provider can connect those dots to your situation far better than a competitive summary can.

Frequently Asked Questions

What tirzepatide products does Eli Lilly make?

Lilly markets tirzepatide as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. It also markets Trulicity (dulaglutide) for type 2 diabetes. Investigational products in Phase 3 include orforglipron and retatrutide, neither of which is FDA-approved.

How does tirzepatide differ from semaglutide?

Tirzepatide is the only FDA-approved GIP/GLP-1 dual agonist, while semaglutide is GLP-1-selective. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes, and SUSTAIN 7 compared semaglutide with dulaglutide. Direct weight-management head-to-head data remains limited, and individual response varies widely.

How much do these branded products cost?

Manufacturer list prices are broadly similar, typically $800-$1,600 per month at U.S. list as of April 2026. Savings programs, insurance coverage, and out-of-pocket cost vary more by product, plan, and indication than by manufacturer. Verify current terms at the time of fill.

Does genetic testing predict which brand will work for me?

No. The Precision Peptide Genetic Test does not predict response to any manufacturer's product. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — context that applies across both Lilly and Novo Nordisk compounds.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.